(NASDAQ: CLRB) Cellectar Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.68%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.82%.
Cellectar Biosciences's earnings in 2025 is -$24,543,492.On average, 2 Wall Street analysts forecast CLRB's earnings for 2025 to be -$22,832,427, with the lowest CLRB earnings forecast at -$23,985,499, and the highest CLRB earnings forecast at -$21,679,201. On average, 3 Wall Street analysts forecast CLRB's earnings for 2026 to be -$24,910,169, with the lowest CLRB earnings forecast at -$39,674,777, and the highest CLRB earnings forecast at -$16,144,086.
In 2027, CLRB is forecast to generate -$29,984,024 in earnings, with the lowest earnings forecast at -$41,978,771 and the highest earnings forecast at -$17,989,124.